Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Memorial Sloan Kettering Cancer Center.
Sponsor:
Collaborators:
Band of Parents
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center.
ClinicalTrials.gov Identifier:
NCT01419834
First received: August 17, 2011
Last updated: November 26, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2015
  Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)